Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bevacizumab + Nab-rapamycin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 10 VEGFR Inhibitor (Pan) 35||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Nab-rapamycin||Fyarro||ABI-009|nab-sirolimus||mTORC1 Inhibitor 9||Fyarro (nab-rapamycin) is nanoparticle albumin-bound rapamycin and inhibitor of mTOR that has immunosuppressant and anti-tumor activities (PMID: 24089446). Fyarro (nab-rapamycin) is FDA approved for use in patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03463265||Phase II||Lomustine + Nab-rapamycin Nab-rapamycin Nab-rapamycin + Temozolomide Bevacizumab + Nab-rapamycin||ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma||Completed||USA||0|